F. Mefti

511 total citations
15 papers, 392 citations indexed

About

F. Mefti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, F. Mefti has authored 15 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in F. Mefti's work include Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (4 papers) and Advanced Breast Cancer Therapies (3 papers). F. Mefti is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (4 papers) and Advanced Breast Cancer Therapies (3 papers). F. Mefti collaborates with scholars based in France, Russia and Estonia. F. Mefti's co-authors include Maya Gutierrez, Étienne Brain, Manon Marcu, Jacques Médioni, Chrystelle Brignone, Joseph Gligorov, Frédéric Triebel, Caroline Grygar, F. Cvitkovic and Véronique Dièras and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

F. Mefti

14 papers receiving 383 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Mefti France	7	325	157	107	45	42	15	392
Inga Rose United States	5	367 1.1×	155 1.0×	121 1.1×	83 1.8×	21 0.5×	8	446
Todd Maney United States	5	389 1.2×	154 1.0×	130 1.2×	100 2.2×	32 0.8×	9	484
Romany Johnpulle United States	8	345 1.1×	123 0.8×	106 1.0×	29 0.6×	15 0.4×	10	436
Laia Garrigós Spain	9	322 1.0×	35 0.2×	177 1.7×	35 0.8×	36 0.9×	35	402
Jonna Berntsson Sweden	7	361 1.1×	226 1.4×	99 0.9×	70 1.6×	13 0.3×	12	473
Ayman Al‐Habeeb Canada	6	170 0.5×	120 0.8×	79 0.7×	27 0.6×	31 0.7×	7	313
Rin Ogiya Japan	8	228 0.7×	74 0.5×	129 1.2×	66 1.5×	22 0.5×	16	305
Nana Scotto Switzerland	7	246 0.8×	38 0.2×	41 0.4×	50 1.1×	20 0.5×	15	333
Shaochuan Liu China	9	237 0.7×	121 0.8×	89 0.8×	54 1.2×	11 0.3×	15	362
D.H. Lee South Korea	6	261 0.8×	147 0.9×	112 1.0×	19 0.4×	12 0.3×	16	386

Countries citing papers authored by F. Mefti

Since Specialization

Citations

This map shows the geographic impact of F. Mefti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Mefti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Mefti more than expected).

Fields of papers citing papers by F. Mefti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Mefti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Mefti. The network helps show where F. Mefti may publish in the future.

Co-authorship network of co-authors of F. Mefti

This figure shows the co-authorship network connecting the top 25 collaborators of F. Mefti. A scholar is included among the top collaborators of F. Mefti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Mefti. F. Mefti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Bonneau, Claire, Gilles Paintaud, Olivier Trédan, et al.. (2018). Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. European Journal of Cancer. 95. 75–84. 66 indexed citations

Gutierrez, Maya, Emmanuelle Fourme, Émilie Le Rhun, et al.. (2015). Abstract P5-19-17: Final results of the phase I "HIT" study: A multicenter phase I-II study evaluating trastuzumab administered by intrathecal injection for leptomeningeal meningitis of HER2+ metastatic breast cancer (MBC). Cancer Research. 75(9_Supplement). P5–19. 2 indexed citations

Aapro, Matti, Yuri E. Demidchik, Igor Bondarenko, et al.. (2014). Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.. Journal of Clinical Oncology. 32(15_suppl). 1013–1013. 2 indexed citations

Martín, Miguel, Y. Demidchik, Igor Bondarenko, et al.. (2014). Vinflunine (Vfl) Plus Capecitabine (Cape) for Advanced Breast Cancer (Abc) Previously Treated with or Resistant to Anthracycline and Resistant to Taxane : a Phase 3 Study Versus Capecitabine. Annals of Oncology. 25. iv119–iv119. 2 indexed citations

Falandry, Claire, Étienne Brain, Marc Bonnefoy, et al.. (2013). Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial. European Journal of Cancer. 49(13). 2806–2814. 28 indexed citations

Campone, Mario, et al.. (2013). A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines. The Breast Journal. 19(3). 240–249. 14 indexed citations

Brundage, Michael, M. Gropp, F. Mefti, et al.. (2012). Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. Annals of Oncology. 23(8). 2020–2027. 30 indexed citations

Saghatchian, Mahasti, et al.. (2012). Results from an observational study (NORA) with oral Navelbine in metastatic breast cancer: A sub-analysis in elderly patients. Journal of Geriatric Oncology. 3. S41–S42. 1 indexed citations

Falandry, Claire, Étienne Brain, Marc Bonnefoy, et al.. (2011). Impact of geriatric vulnerability parameters on pegylated liposomal doxorubicin (PLD) tolerance and outcome in elderly patients with metastatic breast cancer: Results of the DOGMES multicenter phase II GINECO trial.. Journal of Clinical Oncology. 29(15_suppl). 9122–9122. 6 indexed citations

10.

Campone, Mario, Sergei Tjulandin, Shuo Chen, et al.. (2011). P5-19-01: Final Results of a Three-Arm Randomised Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines.. Cancer Research. 71(24_Supplement). P5–19. 2 indexed citations

11.

Brundage, Michael, M. Gropp, F. Mefti, et al.. (2010). Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial.. Journal of Clinical Oncology. 28(15_suppl). 5044–5044.

12.

Brignone, Chrystelle, Maya Gutierrez, F. Mefti, et al.. (2010). First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. Journal of Translational Medicine. 8(1). 71–71. 202 indexed citations

13.

Campone, Mario, S. Tjulandin, F. Mefti, et al.. (2009). 5000 A 3-arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines. European Journal of Cancer Supplements. 7(2). 259–259. 2 indexed citations

14.

Mathiot, Claire, F. Mefti, Suzette Delaloge, et al.. (2009). Single Circulating Tumor Cell Detection and Overall Survival in Non Metastatic Breast Cancer.. Cancer Research. 69(24_Supplement). 3017–3017. 15 indexed citations

15.

Allouache, Djelila, M. Tubiana-Hulin, N. Tubiana-Mathieu, et al.. (2005). First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study. BMC Cancer. 5(1). 151–151. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact